Whole Genome Sequence of the Heterozygous Clinical Isolate Candida krusei 81-B-5

Area of Science:

• Medical Mycology
• Genomics
• Antimicrobial Resistance

Background:

• Candida krusei is an opportunistic fungal pathogen causing infections in immunocompromised individuals.
• This yeast exhibits inherent resistance to fluconazole, a primary antifungal medication.
• C. krusei is also used in cocoa fermentation for chocolate production.

Purpose of the Study:

• To generate a high-quality genome sequence and assembly for a clinical isolate of Candida krusei.
• To identify genetic elements potentially contributing to drug resistance and environmental adaptation.

Main Methods:

• PacBio sequencing technology was employed for genome sequencing and assembly.
• Gene annotation and comparative genomic analysis were performed.
• Analysis of heterozygosity and loss of heterozygosity regions was conducted.

Main Results:

• A high-quality genome sequence and assembly for the clinical isolate C. krusei 81-B-5 were generated into 11 scaffolds.
• A unique profile of transporters potentially involved in drug resistance was identified.
• While 82% of the genome is heterozygous, a 2.0 Mb region showed loss of heterozygosity.

Conclusions:

• The generated genome serves as a valuable reference for Candida krusei.
• Understanding genetic factors, such as transporters and heterozygosity, is crucial for addressing fluconazole resistance.
• This genomic resource will facilitate future research into C. krusei pathogenesis and adaptation.